ERBB2 and breast carcinoma: Although clinical studies have shown that successful trastuzumab therapy is associated with immune cell infiltration, there exists a lack of longitudinal studies that examine trastuzumab-induced CD4 + immune interaction with HER2 + breast cancer [20].